Liver-specific inhibition of CGI-58 is sufficient to induce hepatomegaly, hepatic steatosis, and steatohepatitis in mice (Brown et al., 2010; Sun and Lazar, 2013), indicating that the liver pathologies seen in CDS patients directly originate from CGI-58 deficiency in the liver. This evidence concerns the gene ABHD5 and fatty liver disease.